info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Anti-VEGF Market Research Report Information By Product (Eylea, Lucentis, And Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, And Age-Related Macular Degeneration) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) โ€“ Industry Forecast Till 2032


ID: MRFR/HC/20363-HCR | 128 Pages | Author: Rahul Gotadki| November 2024

Anti-VEGF Market Segmentation


Anti-VEGF Product Outlook (USD Billion, 2019-2032)




  • Eylea




  • Lucentis




  • Beovu




Anti-VEGF Disease Outlook (USD Billion, 2019-2032)




  • Macular Edema




  • Diabetic Retinopathy




  • Retinal Vein Occlusion




  • Age-Related Macular Degeneration




Anti-VEGF Regional Outlook (USD Billion, 2019-2032)




  • North America Outlook (USD Billion, 2019-2032)




    • North America Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • North America Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • US Outlook (USD Billion, 2019-2032)




    • US Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • US Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • CANADA Outlook (USD Billion, 2019-2032)




    • CANADA Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • CANADA Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration








  • Europe Outlook (USD Billion, 2019-2032)




    • Europe Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Europe Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Germany Outlook (USD Billion, 2019-2032)




    • Germany Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Germany Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • France Outlook (USD Billion, 2019-2032)




    • France Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • France Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • UK Outlook (USD Billion, 2019-2032)




    • UK Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • UK Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • ITALY Outlook (USD Billion, 2019-2032)




    • ITALY Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • ITALY Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • SPAIN Outlook (USD Billion, 2019-2032)




    • Spain Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Spain Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Rest Of Europe Outlook (USD Billion, 2019-2032)




    • Rest Of Europe Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • REST OF EUROPE Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration








  • Asia-Pacific Outlook (USD Billion, 2019-2032)




    • Asia-Pacific Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Asia-Pacific Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • China Outlook (USD Billion, 2019-2032)




    • China Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • China Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Japan Outlook (USD Billion, 2019-2032)




    • Japan Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Japan Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • India Outlook (USD Billion, 2019-2032)




    • India Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • India Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Australia Outlook (USD Billion, 2019-2032)




    • Australia Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Australia Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)




    • Rest of Asia-Pacific Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Rest of Asia-Pacific Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration








  • Rest of the World Outlook (USD Billion, 2019-2032)




    • Rest of the World Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Rest of the World Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Middle East Outlook (USD Billion, 2019-2032)




    • Middle East Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Middle East Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Africa Outlook (USD Billion, 2019-2032)




    • Africa Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Africa Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration






    • Latin America Outlook (USD Billion, 2019-2032)




    • Latin America Anti-VEGF by Product




      • Eylea




      • Lucentis




      • Beovu






    • Latin America Anti-VEGF by Disease




      • Macular Edema




      • Diabetic Retinopathy




      • Retinal Vein Occlusion




      • Age-Related Macular Degeneration







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porterโ€™s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Bausch Health Companies Inc.

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ANTI-VEGF MARKET, BY PRODUCT

6.1. Overview

6.2. Eylea

6.3. Lucentis

6.4. Beovu

7. GLOBAL ANTI-VEGF MARKET, BY DISEASE

7.1. Overview

7.2. Macular Edema

7.3. Diabetic Retinopathy

7.4. Retinal Vein Occlusion

7.5. Age-Related Macular Degeneration

8. GLOBAL ANTI-VEGF MARKET, BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Anti-VEGF Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Anti-VEGF Market,

9.7. Key Developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2023

9.8.2. Major Players R&D Expenditure. 2023

10. COMPANY PROFILES

10.1. Regeneron Pharmaceuticals

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Novartis AG

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Roche

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Bayer AG

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Allergan plc

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Pfizer Inc.

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Bausch Health Companies Inc.

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. AbbVie Inc.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Products Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. SANTEN PHARMACEUTICAL CO., LTD.

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Products Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Alcon Inc.

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Products Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANTI-VEGF MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL ANTI-VEGF MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 7 US: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 8 US: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 9 CANADA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 10 CANADA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 3 GERMANY: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 5 FRANCE: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 6 FRANCE: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 7 ITALY: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 8 ITALY: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 9 SPAIN: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 10 SPAIN: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 11 UK: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 12 UK: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 13 REST OF EUROPE: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 14 REST OF EUROPE: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 15 ASIA-PACIFIC: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 16 ASIA-PACIFIC: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 17 JAPAN: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 18 JAPAN: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 19 CHINA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 20 CHINA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 21 INDIA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 22 INDIA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 23 AUSTRALIA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 24 AUSTRALIA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 25 SOUTH KOREA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 26 SOUTH KOREA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 27 REST OF ASIA-PACIFIC: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 28 REST OF ASIA-PACIFIC: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 29 REST OF THE WORLD: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 30 REST OF THE WORLD: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 31 MIDDLE EAST: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 32 MIDDLE EAST: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 33 AFRICA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 34 AFRICA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 35 LATIN AMERICA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 36 LATIN AMERICA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTI-VEGF MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTI-VEGF MARKET

FIGURE 4 GLOBAL ANTI-VEGF MARKET, SHARE (%), BY PRODUCT, 2023

FIGURE 5 GLOBAL ANTI-VEGF MARKET, SHARE (%), BY DISEASE, 2023

FIGURE 6 GLOBAL ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 7 NORTH AMERICA: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 EUROPE: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 ASIA-PACIFIC: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 REST OF THE WORLD: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 GLOBAL ANTI-VEGF MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 12 REGENERON PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 REGENERON PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 14 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 NOVARTIS AG: SWOT ANALYSIS

FIGURE 16 ROCHE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 ROCHE: SWOT ANALYSIS

FIGURE 18 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 BAYER AG: SWOT ANALYSIS

FIGURE 20 ALLERGAN PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 ALLERGAN PLC: SWOT ANALYSIS

FIGURE 22 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 PFIZER INC.: SWOT ANALYSIS

FIGURE 24 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS

FIGURE 26 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 ABBVIE INC.: SWOT ANALYSIS

FIGURE 28 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 SANTEN PHARMACEUTICAL CO., LTD.: SWOT ANALYSIS

FIGURE 30 ALCON INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 ALCON INC.: SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.